Skip to main content

Table 3 Multivariable-adjusted hazard ratios for CHD by MEOX2 haplotypes

From: Coronary risk in relation to genetic variation in MEOX2 and TCF15 in a Flemish population

Haplotype Event N° events/at risk Hazard ratio P P BH
Carrier Non-carrier
TCTTAT      
 All coronary events 40/951 66/1076 0.73 (0.49–1.11) 0.14 0.21
 Myocardial infarction 20 33 0.77 (0.42–1.41) 0.40 0.56
 Coronary revascularisation 30 48 0.75 (0.47–1.19) 0.22 0.22
 Ischaemic cardiomyopathy 6 16 0.56 (0.21–1.51) 0.25 0.25
TCTTGT      
 All coronary events 46/937 60/1090 0.90 (0.58–1.39) 0.63 0.63
 Myocardial infarction 26 27 1.19 (0.67–2.11) 0.56 0.56
 Coronary revascularisation 30 48 0.74 (0.46–1.20) 0.22 0.22
 Ischaemic cardiomyopathy 9 13 0.59 (0.24–1.43) 0.24 0.25
GTCCGC      
 All coronary events 43/614 63/1413 1.78 (1.24–2.56) 0.0018 0.0054
 Myocardial infarction 23 30 1.96 (1.16–3.31) 0.012 0.036
 Coronary revascularisation 33 45 1.87 (1.20–2.91) 0.0058 0.017
 Ischaemic cardiomyopathy 11 11 3.16 (1.41–7.09) 0.0053 0.016
  1. Numbers of events do not add up, because only the first event in each category was analysed. Letters coding the haplotypes refer to the rs10777, rs12056299, rs7787043, rs4532497, rs6959056 and rs1050290 alleles (see Additional file 1: Table S1 and S2). Haplotypes were reconstructed using the expectation-maximisation algorithm as implemented in the PROC HAPLOTYPE procedure of the SAS software version 9.3. Hazard ratios (95 % confidence interval) express the risk associated with carrying vs. not carrying a haplotype, account for family clusters, and were adjusted for baseline characteristics including sex, age, body mass index, systolic pressure, total-to-HDL cholesterol ratio, smoking and drinking, and antihypertensive drug treatment. P and P BH indicate the significance of the hazard ratios without and with Benjamini-Hochberg’s correction for multiple testing